CORINDUS VASCULAR ROBOTICS, INC
CVRS
CVRS was delisted on the 28th of October, 2019.
0 hedge funds and large institutions have $0 invested in CORINDUS VASCULAR ROBOTICS, INC in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 101 closing their positions.
60.83% less ownership
Funds ownership: 60.83% → 0% (-61%)
100% less funds holding
Funds holding: 101 → 0 (-101)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $543M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 101
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HealthCor Management
New York
|
-$85.5M |
| 2 |
HEC
Hudson Executive Capital
New York
|
-$60.9M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$46.5M |
| 4 |
Alpine Associates Management
Palm Beach,
Florida
|
-$39.5M |
| 5 |
Sand Grove Capital Management
London,
United Kingdom
|
-$30.8M |
CVRS Hedge Fund Activity: Q4 2019 in Review
0 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in CORINDUS VASCULAR ROBOTICS, INC (CVRS) for Q4 2019, worth a combined $0 — down 100% from $543M a quarter earlier.
Sellers outnumbered buyers: 101 funds closed out of CVRS and 0 opened new positions — a net loss of 101 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was HealthCor Management, exiting entirely with an estimated $85.5M sold.
- 0 institutional investors held CORINDUS VASCULAR ROBOTICS, INC (CVRS) as of Q4 2019, down from 101 in Q3 2019.
- Funds reported $0 of CORINDUS VASCULAR ROBOTICS, INC stock for Q4 2019, down 100% quarter-over-quarter.
- 0 funds opened new CORINDUS VASCULAR ROBOTICS, INC positions in Q4 2019 and 101 closed out, a net change of -101 holders.
- The largest CORINDUS VASCULAR ROBOTICS, INC seller in Q4 2019 was HealthCor Management, an estimated $85.5M sold.
Based on aggregated 13F filings for Q4 2019.